Redeye provides its initial comments on Scandinavian ChemoTech's rights issue announced this morning. The company is raising SEK13.84m at a 25% discount to finance further sales efforts and to pay off debt. We had already modelled a capital raise in our valuation, although with a higher discount. We will await the outcome of the rights issue before making any formal changes to our estimates.
LÄS MER